Forum Topic News
  • Conversation: US expands scope of Seattle Genetics’ Adcetris

    • March 21, 2018 12:39 PM GMT
      • Post(s)
        557

      US expands scope of Seattle Genetics’ Adcetris

      US regulators have approved Seattle Genetics’ Adcetris in combination with chemotherapy for adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma.
      The decision gives patients in this setting the first new treatment option in more than 40 years, the firm notes.
      Read more: http://www.pharmatimes.com/news/us_expands_scope_of_seattle_genetics_adcetris_1228673

Add Reputation

Do you want to add reputation for this member by this post?

or cancel